Aminoguanidine exhibits an inhibitory effect on β‑amyloid‑induced damage in F98 glioma cells

Chen,Tao; Sun,Xiao‑Li; Yang,Xi‑Ai; Shi,Jing‑Jing; Liu,Yi; Gong,Jia‑Ming

doi:10.3892/mmr.2017.7378

Aminoguanidine exhibits an inhibitory effect on β‑amyloid‑induced damage in F98 glioma cells

Authors:
- Tao Chen
- Xiao‑Li Sun
- Xi‑Ai Yang
- Jing‑Jing Shi
- Yi Liu
- Jia‑Ming Gong
View Affiliations

Affiliations: Department of Neurology, Ankang City Central Hospital, Ankang, Shaanxi 725000, P.R. China, Department of Neurology, Shangluo Central Hospital, Shangluo, Shaanxi 726000, P.R. China
Published online on: August 29, 2017 https://doi.org/10.3892/mmr.2017.7378
Pages: 6116-6121

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study investigated the role of aminoguanidine in the prevention of harmful effects in astroglioma F98 cells induced by β‑amyloid treatment. MTT assay was used to analyze cell viability. Expression of inducible nitric oxide synthase (iNOS) was analyzed using western blot analysis. Treatment of the F98 cells with a 15 µM concentration of β‑amyloid for 12 h reduced cell viability to 18% compared with the control cells. However, pretreatment with a 30 µM concentration of aminoguanidine for 12 h completely prevented the β‑amyloid‑induced reduction in cell viability. The production of ROS and the expression of iNOS were significantly (P<0.005) higher in the β‑amyloid‑treated F98 cells. Aminoguanidine pre‑treatment inhibited the β‑amyloid‑induced increase in the expression of ROS, with increased mRNA and proteins levels of iNOS12 h following treatment at a 30 µM concentration. The β‑amyloid treatment also resulted in a marked increase in the expression of cyclooxygenase‑2 (COX‑2) in F98 cells. By contrast, pre‑treatment with aminoguanidine for 12 h led to reduction in the mRNA and protein expression levels of COX‑2. Pre‑treatment of the F98 cells with aminoguanidine at a 30 µM concentration for 12 h prior to incubation with β‑amyloid significantly (P<0.002) reduced the expression of prostaglandin E2 (PGE2). Aminoguanidine pre‑treatment also caused the inhibition of β‑amyloid‑induced translocation of nuclear factor (NF)‑κB p65 into the cytosol. Thus, aminoguanidine prevented β‑amyloid‑induced Alzheimer's disease through reductions in the expression levels of NO, iNOS, PGE2 and COX‑2, and the inactivation of NF‑κB. Therefore, aminoguanidine offers potential for use in the treatment of neurological disorders, including Alzheimer's disease.

View Figures

View References

1	Lewczuk P, Kamrowski-Kruck H, Peters O, Heuser I, Jessen F, Popp J, Bürger K, Hampel H, Frölich L, Wolf S, et al: Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: A multicenter study. Mol Psychiatry. 15:138–145. 2010. View Article : Google Scholar : PubMed/NCBI
2	Weiner MW: Dementia in 2012: Further insights into Alzheimer disease pathogenesis. Nat Rev Neurol. 2:65–66. 2013. View Article : Google Scholar
3	Tan L, Yu JT, Hu N and Tan L: Non-coding RNAs in Alzheimer's disease. Mol Neurobiol. 47:382–393. 2013. View Article : Google Scholar : PubMed/NCBI
4	Eckert A, Keil U, Marques CA, Bonert A, Frey C, Schüssel K and Müller WE: Mitochondrial dysfunction, apoptotic cell death, and Alzheimer's disease. Biochem Pharmacol. 66:1627–1634. 2003. View Article : Google Scholar : PubMed/NCBI
5	Canevari L, Abramov AY and Duchen MR: Toxicity of amyloid beta peptide: Tales of calcium, mitochondria, and oxidative stress. Neurochem Res. 29:637–650. 2004. View Article : Google Scholar : PubMed/NCBI
6	Grundman M, Grundman M and Delaney P: Antioxidant strategies for Alzheimer's disease. Proc Nutr Soc. 61:191–202. 2002; View Article : Google Scholar : PubMed/NCBI
7	Komatsu M and Hiramatsu M: The efficacy of an antioxidant cocktail on lipid peroxide level and superoxide dismutase activity in aged rat brain and DNA damage in iron-induced epileptogenic foci. Toxicology. 148:143–148. 2000. View Article : Google Scholar : PubMed/NCBI
8	Bastianetto S, Zheng WH and Quirion R: Neuroprotective abilities of resveratrol and other red wine constituents against nitric oxide-related toxicity in cultured hippocampal neurons. Br J Pharmacol. 131:711–720. 2000. View Article : Google Scholar : PubMed/NCBI
9	Abdel-Rahman E and Bolto WK: Pimagedine: A novel therapy for diabetic nephropathy. Expert Opin Investig Drugs. 11:565–574. 2002. View Article : Google Scholar : PubMed/NCBI
10	Di F, Yan-Ting G, Hui L, Tao T, Zai-Hua X, Xue-Ying S, Hong-Li X and Yun-Jie W: Role of aminoguanidine in brain protection in surgical brain injury in rat. Neurosci Let. 448:204–207. 2008. View Article : Google Scholar
11	Sugimoto K and Iadecola C: Effects of aminoguanidine on cerebral ischemia in mice: Comparison between mice with and without inducible nitric oxide synthase gene. Neurosci Lett. 331:25–28. 2002. View Article : Google Scholar : PubMed/NCBI
12	Louin G, Marchand-Verrecchia C, Palmier B, Plotkine M and Jafarian-Tehrani M: Selective inhibition of inducible nitric oxide synthase reduces neurological deficit but not cerebral edema following traumatic brain injury. Neuropharmacology. 50:182–190. 2006. View Article : Google Scholar : PubMed/NCBI
13	Pearse DD, Chatzipanteli K, Marcillo AE, Bunge MB and Dietrich WD: Comparison of iNOS inhibition by antisense and pharmacological inhibitors after spinal cord injury. J Neuropathol Exp Neurol. 62:1096–1107. 2003. View Article : Google Scholar : PubMed/NCBI
14	Hardy JA and Higgins GA: Alzheimer's disease: The amyloid cascade hypothesis. Science. 256:184–185. 1992. View Article : Google Scholar : PubMed/NCBI
15	Yankner BA, Dawes LR, Fisher S, Villa-Komaroff L, Oster-Granite ML and Neve RL: Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science. 245:417–420. 1989. View Article : Google Scholar : PubMed/NCBI
16	Raivich G, Jones LL, Werner A, Bluthmann H, Doetschmann T and Kreutzberg GW: Molecular signals for glial activation: Pro- and anti-inflammatory cytokines in the injured brain. Acta Neurochir Suppl. 73:S21–S30. 1999.
17	Pasinetti GM: From epidemiology to therapeutic trials with anti-inflammatory drugs in Alzheimer's disease: The role of NSAIDs and cyclooxygenase in beta-amyloidosis and clinical dementia. J Alzheimers Dis. 4:435–445. 2002. View Article : Google Scholar : PubMed/NCBI
18	Montine TJ, Sidell KR, Crews BC, Markesbery WR, Marnett LJ, Roberts LJ and Morrow JD: Elevated CSF prostaglandin E2 levels in patients with probable AD. Neurology. 53:1495–1498. 1999. View Article : Google Scholar : PubMed/NCBI
19	Duncan AJ and Heales SJ: Nitric oxide and neurological disorders. Mol Aspects Med. 26:67–96. 2005. View Article : Google Scholar : PubMed/NCBI
20	MacMicking J, Xie QW and Nathan C: Nitric oxide and macrophage function. Annu Rev Immunol. 15:323–350. 1997. View Article : Google Scholar : PubMed/NCBI
21	Terai K, Matsuo A and McGeer PL: Enhancement of immunoreactivity for NF-kappa B in the hippocampal formation and cerebral cortex of Alzheimer's disease. Brain Res. 735:159–168. 1996. View Article : Google Scholar : PubMed/NCBI
22	Akama KT and van Eldik LJ: Beta-amyloid stimulation of inducible nitric-oxide synthase in astrocytes is interleukin-1beta- and tumor necrosis factor-alpha (TNFalpha)-dependent, and involves a TNFalpha receptor-associated factor- and NFkappaB-inducing kinase-dependent signaling mechanism. J Biol Chem. 275:7918–7924. 2000. View Article : Google Scholar : PubMed/NCBI